We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24% → 103.27% (+1%)

4% less funds holding

Funds holding: 179 → 171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M

Top Buyers

1
SL
Siren LLC
Connecticut
+$17.3M
2
Franklin Resources
Franklin Resources
California
+$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11M
4
Barclays
Barclays
United Kingdom
+$9.52M
5
JAM
Jupiter Asset Management
United Kingdom
+$8.12M

Top Sellers

1
SI
Sofinnova Investments
California
-$6.37M
2
SCM
Silverarc Capital Management
Massachusetts
-$6.12M
3
Ameriprise
Ameriprise
Minnesota
-$6.07M
4
PSC
Patient Square Capital
California
-$4.23M
5
NCM
Nantahala Capital Management
Connecticut
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
VFA
126
Valeo Financial Advisors
Indiana
$139K -$70.3K -5,000 -33%
MCM
127
MAI Capital Management
Ohio
$125K +$127K +9,014 New
ACM
128
ACT Capital Management
Pennsylvania
$125K – – –
TRCT
129
Tower Research Capital (TRC)
New York
$110K -$2.56K -182 -2%
AIP
130
Ameritas Investment Partners
Nebraska
$100K – – –
Mirae Asset Global Investments
131
Mirae Asset Global Investments
South Korea
$79.6K +$5.5K +391 +7%
SO
132
STRS Ohio
Ohio
$47.3K – – –
GFM
133
GF Fund Management
China
$34.1K +$4.18K +297 +14%
LWCFA
134
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$29.5K – – –
US Bancorp
135
US Bancorp
Minnesota
$28.7K +$886 +63 +3%
SOW
136
State of Wyoming
Wyoming
$26.2K +$7.06K +502 +36%
KBC Group
137
KBC Group
Belgium
$26K +$26.2K +1,863 New
AAP
138
Arax Advisory Partners
Colorado
$20.8K -$14.9K -1,056 -41%
BNP Paribas Asset Management
139
BNP Paribas Asset Management
France
$19.7K +$1.45K +103 +8%
Rockefeller Capital Management
140
Rockefeller Capital Management
New York
$17.7K +$14.2K +1,013 +388%
Carson Wealth (CWM LLC)
141
Carson Wealth (CWM LLC)
Nebraska
$17.6K +$985 +70 +6%
SCM
142
Sterling Capital Management
North Carolina
$15.8K -$6.89K -490 -30%
SPIA
143
Steward Partners Investment Advisory
New York
$13.9K -$7.03K -500 -33%
Nisa Investment Advisors
144
Nisa Investment Advisors
Missouri
$12.8K – – –
WA
145
Westfuller Advisors
New York
$11.4K – – –
Fifth Third Bancorp
146
Fifth Third Bancorp
Ohio
$10.5K +$10.6K +755 New
MAM
147
Meeder Asset Management
Ohio
$9.19K -$20.2K -1,438 -69%
DF
148
Dunhill Financial
United Kingdom
$8.34K – – –
Osaic Holdings
149
Osaic Holdings
Arizona
$7.34K +$3.92K +279 +112%
GI
150
GAMMA Investing
California
$5.8K +$2.11K +150 +56%
4 5
6
7 8

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.